Linkedin
RLS logo_header
Linkedin

Development of CT-0525 program to be discontinued

“These strategic initiatives, re-directing our investments to the in vivo macrophage engineering platform, discontinuing development of our anti-HER2 program and reducing our workforce, aim to streamline our operations and reduce operating expenses over time,” said Steven Kelly, President and Chief Executive Officer of Carisma. “While these decisions are very challenging, they are made in the best interest of our shareholders. We remain deeply grateful for the significant contributions of the employees departing Carisma.”

Read the full story on "Development of CT-0525 program to be discontinued"

Share:

More News

Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline

“This acquisition further strengthens our late-stage oncology pipeline and reflects our continued focus on bringing transformational treatments to people living with cancer,” said David Loew, CEO, Ipsen. “We are excited by the potential of navtemadlin to define a new treatment paradigm for patients with myelofibrosis who have a suboptimal response

Excalipoint Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate EXP011 in DLL3‑Expressing Solid Tumors

“We are pleased to partner with Roche to explore the combination potential of EXP011 and atezolizumab for patients with SCLC and other hard-to-treat solid tumors.” said Lei Fang, Ph.D., Co-Founder, Chairman and Chief Executive Officer, Excalipoint Therapeutics. “This collaboration enables us to evaluate a differentiated immuno-oncology combination strategy to address

Positive Ph 3 Results for BRUKINSA in Frontline MCL Announced

Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “For patients with newly diagnosed MCL, chemotherapy is currently the default. MANGROVE demonstrates for the first time that BRUKINSA plus rituximab, a chemotherapy-free regimen, can deliver unprecedented improvements in progression-free survival, potentially redefining the treatment paradigm globally. We believe

Novartis to acquire Myricx Bio for ADCs with N-myristoyltransferase inhibitor (NMTi) payloads

“ADCs have become an important part of cancer treatment, but there remains a clear need for new payload mechanisms to overcome resistance and expand their impact for patients,” said Fiona Marshall, President of Biomedical Research at Novartis. “Myricx Bio has developed a promising NMTi payload platform with a differentiated mechanism